Barbara Klencke (NASDAQ: ALXO) reports option and stock holdings
Rhea-AI Filing Summary
ALX Oncology Holdings Inc Chief Medical Officer Barbara Klencke filed an initial Form 3 reporting her equity interests in the company. She lists several stock option awards and common stock positions, reflecting both direct and indirect ownership.
The filing reports stock options over 40,400, 300,000 and 100,000 shares, plus 60,000 common shares held directly and another 60,000 common shares held indirectly by her spouse. Footnotes describe vesting schedules for the options, with installments beginning on February 21, 2025, September 17, 2025, January 31, 2026, June 30, 2026 and February 26, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Klencke Barbara
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 440,400 shares (Direct);
Common Stock — 60,000 shares (Direct);
Common Stock — 60,000 shares (Indirect, See footnote)
Footnotes (4)
- F1. The shares are held directly by the reporting person's spouse.
- F2. Shares subject to the option vest in 36 equal monthly installments beginning on February 21, 2025.
- F3. One-third of the shares subject to the option vest on each of September 17, 2025, January 31, 2026 and June 30, 2026.
- F4. Shares subject to the option vest in 12 equal monthly installments beginning on February 26, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider holdings did Barbara Klencke report in ALXO on this Form 3?
Barbara Klencke reported stock options over 40,400, 300,000 and 100,000 ALX Oncology shares, plus 60,000 common shares held directly. She also disclosed an additional 60,000 common shares held indirectly through her spouse as noted in a filing footnote.
How are Barbara Klencke’s ALXO stock options structured and when do they vest?
Her options have time-based vesting schedules. One grant vests in 36 equal monthly installments beginning February 21, 2025. Another vests one-third on each of September 17, 2025, January 31, 2026 and June 30, 2026. A further grant vests in 12 equal monthly installments starting February 26, 2026.
What indirect ALXO ownership did Barbara Klencke disclose on the Form 3?
She disclosed 60,000 ALX Oncology common shares as indirect ownership. A footnote explains these shares are held directly by her spouse. The filing classifies this position as indirect, reflecting that the shares are not held in her own name.
Does Barbara Klencke’s ALXO Form 3 show any insider buying or selling activity?
The Form 3 lists holdings only and does not show insider buying or selling. All entries are coded as holdings with unknown transaction codes, and the transaction summary reports zero buy shares, zero sell shares, and a neutral net buy/sell direction.